Trial Profile

A Randomized Phase II Study to Assess the Activity of TroVax (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVA 5T4 (Primary) ; Docetaxel
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Sponsors Oxford BioMedica

Most Recent Events

29 Jul 2013 Results will be published in Cancer Immunology, Immunotherapy, in 2013, according to an Oxford BioMedica media release reporting highlights.
10 Oct 2012 Verified results data from the 27 enrolled patients will be presented at the first Immunotherapies and Cancer Vaccines Conference in December 2012.
10 Oct 2012 Status changed from recruiting to discontinued, as reported by Oxford BioMedica in a media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com